AbMax Bio Announces Successful Development of Antibodies to New Coronary Virus

Since December 2019, more than 200 cases of pneumonia caused by the new coronavirus have been confirmed in Wuhan, Beijing, Shenzhen and Japan and Thailand, China, and serious deaths have been reported.

AbMax biotechnology team was informed of the outbreak on January 2, immediately cooperate with the disease control department, using our confidential antigen design software and the world’s leading antibody preparation technology, only 17 days to complete the peptide design, synthesis, coupling and animal immunity, on the 19th successfully developed a recognizable 2019 coronavirus N protein antibody, Provide key technical support for responding to major outbreaks of infectious diseases!

In 2008, when the outbreak of hand-foot-mouth virus EV71 broke out in China, under the organization of the Beijing Municipal Science and Technology Commission, with the China Center for Disease Control and Prevention, National Pharmaceutical Group and other advantages of cooperation, AbMax in just 35 days to successfully develop the world’s first with neutralactivit of the hands and feet EV71 monoclonal antibody, Contributed to china’s global first ev71 vaccine. 2009 H1N1 influenza, 2010 New Bonia virus, H7N9 avian influenza, Ebola virus, Zika virus… In each outbreak, the emergency team is not missing the name of AbMax. Over the years, as one of the sponsors of Beijing’s emergency response platform for infectious diseases, AbMax has made important contributions to China’s public health and emergency response to infectious diseases.

Jingtiancheng Bio Announces Successful Development of Antibodies to New Coronary Virus